Last updated: August 3, 2026
Hydrocodone bitartrate and homatropine methylbromide is a mature opioid antitussive combination with limited protection from composition-of-matter patents and no biologic exclusivity barrier. Commercial value is concentrated in formulation execution, supply reliability, dosage-form differentiation, and regulatory control rather than in core molecule protection. The strongest opportunities are sugar-free and alcohol-free liquids, taste-masked products, unit-dose packaging, tablet lifecycle management, and compliant generic or 505(b)(2) development.
What is the regulatory and commercial status of hydrocodone bitartrate and homatropine methylbromide?
Hydrocodone bitartrate and homatropine methylbromide is an oral cough suppressant combination. Hydrocodone provides opioid antitussive activity. Homatropine methylbromide is included in a low dose to discourage intentional ingestion of excessive quantities of hydrocodone.
The product has been marketed under the Hycodan brand and through multiple generic products. FDA-approved dosage forms include oral tablets and oral solutions. The product is federally regulated as a Schedule II controlled substance because it contains hydrocodone.[1,2]
| Attribute |
Commercial status |
| Active ingredients |
Hydrocodone bitartrate and homatropine methylbromide |
| Main therapeutic use |
Cough suppression |
| Dosage forms |
Tablets and oral solutions |
| FDA pathway for generics |
Abbreviated New Drug Application |
| Controlled-substance status |
Schedule II |
| Biologic product |
No |
| Biosimilar pathway |
Not applicable |
| Core patent position |
Mature, with limited practical value from original molecule patents |
| Primary barriers |
DEA controls, opioid manufacturing quotas, formulation quality, supply-chain security, and FDA approval |
FDA labeling restricts use in children younger than six years and includes opioid-related warnings concerning respiratory depression, misuse, addiction, and overdose.[1,2]
What excipients are used in hydrocodone-homatropine products?
Excipient selection depends on whether the product is a tablet, conventional syrup, sugar-free solution, or concentrated unit-dose liquid. Published labels identify different inactive ingredients by manufacturer, so the excipient profile is not uniform across the market.
Oral tablets
Tablet formulations commonly use:
- Lactose or another compressible diluent
- Microcrystalline cellulose
- Povidone or another binder
- Croscarmellose sodium or comparable disintegrant
- Magnesium stearate
- Colloidal silicon dioxide
- Film-coating materials where applicable
The principal development issues are content uniformity at a low active load, tablet weight control, hardness, friability, dissolution, and prevention of hydrocodone segregation during blending.
Hydrocodone bitartrate and homatropine methylbromide are present in relatively small quantities compared with the tablet mass. A direct-compression process can be commercially attractive, but it requires robust powder-flow and segregation studies. Wet granulation may improve uniformity but adds processing time and introduces moisture and drying variables.
Conventional oral solutions
Liquid products may contain:
- Purified water
- Sucrose
- Glycerin
- Propylene glycol
- Sodium citrate
- Citric acid
- Flavoring agents
- Preservatives such as methylparaben
- Colorants
Sucrose improves palatability and viscosity but creates concerns for diabetic patients, dental health, and pediatric positioning. Propylene glycol can improve solubilization and mouthfeel, but its concentration requires control because of regulatory scrutiny in vulnerable populations. Preservatives must be justified through antimicrobial effectiveness testing and container-closure studies.
Sugar-free and alcohol-free liquids
A commercially differentiated liquid can replace sucrose with a combination of sorbitol, glycerin, maltitol, or another polyol system. The formulation must control:
- Osmolality
- Gastrointestinal tolerance
- Viscosity
- Sedimentation or crystallization
- Taste persistence
- Microbial stability
- Fill-volume accuracy
An alcohol-free formula can improve positioning for pediatric and family-use settings. It also removes a potential objection from hospitals, caregivers, and institutional buyers. The absence of ethanol does not remove the product's opioid risks or controlled-substance obligations.
What excipient strategy best supports a differentiated product?
The highest-value strategy is to treat excipients as part of a controlled-delivery and usability platform rather than as low-cost inactive materials.
Taste masking
Hydrocodone can produce bitter or unpleasant oral sensory characteristics. Homatropine methylbromide may also affect taste at the formulation level. Taste masking can use:
- Flavor systems with bitterness suppression
- Ion-exchange resins
- Polymer coating
- Cyclodextrin complexation
- Lipid or multiparticulate barriers
- pH adjustment
- Viscosity modification
A simple flavor change is unlikely to create durable intellectual property. A patentable product would need a defined excipient ratio, particle coating, release profile, manufacturing process, or sensory-performance relationship.
Abuse-deterrent formulation
A conventional syrup is not an abuse-deterrent formulation under FDA's abuse-deterrent opioid framework merely because it contains homatropine methylbromide. A product seeking abuse-deterrent labeling would require formulation-specific evidence and FDA review under applicable guidance.[3]
Potential technologies include:
- Increased viscosity to resist rapid dose extraction
- Gel formation after tampering
- Physical barriers to crushing
- Sequestration of hydrocodone
- Controlled release
- Aversion systems
These approaches carry significant development cost. They can also change bioavailability, dose titration, and the risk-benefit profile. The commercial case is stronger for a high-volume opioid analgesic than for a mature antitussive product with comparatively limited market demand.
Preservative system
Multidose oral liquids need an effective antimicrobial strategy. A preservative-free product may have value in hospital, compounding, or sensitive-patient settings, but it generally requires single-dose packaging or validated in-use stability.
Potential approaches include:
- Preservative-containing multidose packaging
- Unit-dose ampules or cups
- Blow-fill-seal containers
- Antimicrobial container systems
- Low-water-activity formulations
Preservative selection must be assessed against pH, container compatibility, flavor, adsorption, and regulatory limits. A technically simple preservative system may be more commercially attractive than a premium preservative-free product if the target market is retail pharmacy.
What patent opportunities exist for the excipient platform?
The original active-ingredient combination is old. The practical IP opportunity is therefore concentrated in secondary patents.
Formulation patents
Potential claim areas include:
- Sugar-free hydrocodone-homatropine oral solutions
- Alcohol-free formulations
- Defined taste-masking systems
- Low-sedimentation liquids
- Preservative systems
- Unit-dose packaging with specified stability
- Improved tablet dissolution
- Reduced hydrocodone segregation
- Moisture-resistant tablets
- Abuse-deterrent dosage forms
- Pediatric-friendly flavor and viscosity systems
A strong formulation patent should include comparative data against a conventional product. Useful evidence includes improved chemical stability, reduced degradation, better content uniformity, lower extractability, longer in-use stability, or clinically relevant palatability.
Method-of-use patents
Potential method-of-use claims are narrower because cough treatment is an established use. Possible targets include:
- Treatment of a defined cough subtype
- Use in a specified patient population
- Dosing under a controlled titration regimen
- Use with a defined concomitant therapy
- Reduction of opioid exposure through a particular dosing method
These claims face substantial validity and infringement risks if they merely restate known administration of the approved product. Commercial value is more likely where the method addresses a clearly defined clinical population and has supporting clinical evidence.
Manufacturing and process patents
Manufacturing IP may cover:
- Low-shear blending that improves content uniformity
- Granulation conditions
- API particle-size control
- Hydrocodone-homatropine co-processing
- Liquid dissolution order
- Deaeration and filling
- Container-closure systems
- Stability-improving pH control
Process patents are commercially useful when they reduce batch failures or create a measurable quality advantage. They are harder to enforce against a generic manufacturer unless the protected process is necessary for the marketed product.
What is the Orange Book and exclusivity position?
Hydrocodone bitartrate and homatropine methylbromide is a mature small-molecule product. It does not have biologic exclusivity, so biosimilar competition is irrelevant. Generic competition proceeds through the ANDA pathway rather than through biosimilar applications.
The original product's regulatory exclusivity periods have expired. Any current patent value would depend on specific, still-active listings associated with a particular reference product and dosage form. Orange Book records should be reviewed by NDA, strength, dosage form, and patent-use code because listings can differ between tablets and oral solutions.[4]
| Protection category |
Practical assessment |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not a principal protection mechanism |
| Pediatric exclusivity |
No current commercial barrier expected from the original product |
| Biosimilar exclusivity |
Not applicable |
| Core composition patent |
Historic protection, not a current entry barrier |
| Formulation patents |
Potentially relevant only if separately developed and listed |
| Method-of-use patents |
Potentially relevant but narrower and litigation-sensitive |
| Generic pathway |
ANDA, subject to applicable reference-product requirements |
When does hydrocodone-homatropine lose exclusivity?
The product has already lost the commercially meaningful exclusivity associated with its original approval. Market entry is therefore governed by FDA approval requirements, DEA controls, manufacturing capacity, and any active formulation or use patents rather than by a single future patent cliff.
A generic applicant may need to address:
- Bioequivalence for the relevant dosage form.
- Pharmaceutical equivalence and active-ingredient specifications.
- Controlled-substance registration and quota requirements.
- CMC validation and stability.
- Labeling and risk-management obligations.
- Any listed patents through a Paragraph III or Paragraph IV certification.
Which companies are challenging the branded market?
The market has historically included multiple generic manufacturers and distributors rather than one dominant challenger. Participation can change because opioid manufacturing quotas, compliance actions, supply disruptions, and portfolio decisions affect availability.
A generic company entering this category must compete on:
- Consistent API supply
- DEA quota access
- Reliable fill-finish capacity
- Retail wholesaler relationships
- Low complaint rates
- Controlled-substance security
- Shortage avoidance
- Competitive pricing
The branded opportunity is constrained by the presence of generic tablets and liquids. A new entrant is more likely to succeed with a differentiated formulation, contract-manufacturing model, or supply-reliability proposition than with an undifferentiated tablet.
What Paragraph IV risks apply?
A Paragraph IV challenge is relevant only if an applicant seeks approval before expiration of an applicable listed patent. For a mature hydrocodone-homatropine product, the principal risk would arise from secondary patents covering:
- Liquid formulation composition
- Abuse-deterrent technology
- Controlled-release architecture
- Packaging
- Method of treating cough
- Manufacturing process
If no enforceable listed patent covers the target dosage form, the applicant's principal risks shift away from patent litigation and toward FDA deficiencies, bioequivalence failure, DEA controls, and commercial launch economics.
A patent holder can file suit after receiving a Paragraph IV notice, potentially triggering a 30-month stay under the Hatch-Waxman framework. The commercial significance of such litigation depends on the patent's claim scope, Orange Book listing, and whether the generic applicant has carved out the patented method of use.[5]
What generic launch scenarios exist?
Immediate or low-friction generic launch
This scenario applies when:
- No enforceable listed patent blocks the product
- The applicant completes ANDA review
- Bioequivalence is straightforward
- DEA quota is available
- Commercial manufacturing is validated
The likely product is a conventional tablet or oral solution with limited differentiation.
Formulation-led launch
A company can target a sugar-free, alcohol-free, better-tasting, or unit-dose product. The FDA pathway may be an ANDA if the product remains pharmaceutically equivalent, or a 505(b)(2) application if it differs materially in formulation, dosage form, delivery, or clinical use.[6]
Premium institutional launch
A preservative-free unit-dose liquid or tamper-resistant product could target hospitals, emergency departments, correctional health systems, and specialty pharmacies. The market would be smaller, but procurement may value standardized dosing and controlled inventory.
Supply-disruption launch
A manufacturer with secure API sourcing and excess controlled-substance capacity can capture share during shortages. This opportunity is operational rather than patent-based and depends on regulatory compliance and supply continuity.
How does hydrocodone-homatropine compare with competing cough products?
| Product category |
Main advantage |
Main weakness |
Excipient opportunity |
| Hydrocodone-homatropine |
Established opioid antitussive combination |
Schedule II controls and opioid safety concerns |
Sugar-free liquids, taste masking, unit-dose packaging |
| Codeine antitussives |
Familiar low-cost category |
Opioid restrictions and variable metabolism concerns |
Pediatric and safety positioning is limited |
| Benzonatate |
Non-opioid prescription option |
Swallowing and overdose hazards |
Improved capsule identification and packaging |
| Dextromethorphan |
Broad OTC access |
Abuse potential at high doses and weaker prescription positioning |
Taste, sustained release, and combination products |
| Non-opioid prescription syrups |
Lower controlled-substance burden |
May provide weaker cough suppression for some patients |
Sugar-free, alcohol-free, and preservative-free formats |
The product's commercial differentiation is strongest where prescribers or institutions still value opioid antitussive activity but require improved administration, packaging, or supply reliability.
What commercial opportunities exist for manufacturers and licensors?
Excipient and formulation licensing
Licensable assets could include:
- Proprietary bitterness blockers
- Hydrocodone sequestration systems
- High-viscosity liquids
- Pediatric flavor platforms
- Preservative-free unit-dose packaging
- Stability-enhancing pH systems
- Direct-compression tablet technology
The license should be supported by comparative analytical data and a clear FDA pathway. A generic excipient package without regulatory differentiation is unlikely to command significant royalties.
Contract development and manufacturing
CDMOs can offer value through:
- Controlled-substance handling
- Small-batch liquid filling
- DEA-compliant inventory management
- Unit-dose packaging
- Stability programs
- Scale-up of low-dose tablets
- Serialization and secure distribution
Controlled-substance capability is a real entry barrier for smaller firms, even where patent protection is weak.
Private-label and institutional products
Pharmacies, hospitals, and regional distributors may seek private-label products with:
- Consistent supply
- Multiple concentrations
- Unit-dose formats
- Barcoded packaging
- Sugar-free formulations
- Simplified medication administration
The opportunity is volume-sensitive and generally depends on winning contracts rather than establishing a premium consumer brand.
How strong is the patent estate for hydrocodone-homatropine products?
The core patent estate is weak from a modern market-entry perspective because the active-ingredient combination is long established and generic alternatives exist. A new formulation patent could be moderately valuable if it protects a clinically relevant feature that cannot be easily designed around.
Patent strength is highest when claims cover:
- A narrow but necessary excipient combination
- A measurable stability or bioavailability advantage
- A distinctive abuse-deterrent mechanism
- A dosage form with commercial demand
- A manufacturing step that competitors cannot readily replace
Patent strength is lower when claims cover:
- Routine flavor changes
- Broad lists of conventional excipients
- Unsubstantiated taste claims
- Generic pH or viscosity ranges
- A known cough indication without a defined technical improvement
What geographic coverage matters?
The United States is the most legally complex market because of FDA approval, Orange Book listings, Hatch-Waxman litigation, DEA scheduling, and opioid quota controls. European and other markets have separate requirements for controlled substances, pediatric use, excipient acceptability, and prescription classification.
A global formulation strategy should assess:
- Country-specific opioid scheduling
- Import and export permits
- Excipient restrictions
- Pediatric labeling
- Alcohol content
- Sugar content
- Preservative requirements
- Serialization
- Local manufacturing rules
- Patent status by jurisdiction
A U.S. formulation patent does not create equivalent protection in Europe, Canada, Japan, or emerging markets. Conversely, a product may face regulatory restrictions abroad even where patent barriers are absent.
Key Takeaways
- Hydrocodone bitartrate and homatropine methylbromide is a mature Schedule II oral antitussive with expired core exclusivity.
- Biosimilar risk does not apply because the product is a small-molecule drug.
- Commercial value is concentrated in formulation, packaging, manufacturing reliability, and controlled-substance compliance.
- The strongest excipient opportunities are sugar-free, alcohol-free, taste-masked, preservative-free, and unit-dose liquids.
- Tablet development requires tight control of low-dose content uniformity, segregation, dissolution, and moisture exposure.
- A new formulation may use an ANDA only if it remains pharmaceutically equivalent; material differences may require a 505(b)(2) application.
- Patent value is more likely to arise from a demonstrated technical effect than from routine excipient substitution.
- Paragraph IV risk depends on active Orange Book-listed patents for the specific reference product and dosage form.
- Supply continuity and DEA quota access may be more important commercially than patent exclusivity.
- Licensing value is strongest for validated abuse-deterrent, taste-masking, stability, or unit-dose technologies.
FAQs
Can hydrocodone-homatropine be reformulated as a sugar-free syrup?
Yes. A sugar-free formulation can use polyols and viscosity modifiers, but the developer must establish palatability, microbial control, osmolality, stability, and bioequivalence or clinical bridging as required by the FDA pathway.
Is hydrocodone-homatropine suitable for a 505(b)(2) product?
Potentially. A 505(b)(2) strategy may be appropriate for a materially different dosage form, delivery system, abuse-deterrent design, or clinically supported formulation change that cannot qualify as an ANDA product.
Does homatropine methylbromide make hydrocodone abuse-deterrent?
No. Its presence does not by itself establish FDA-recognized abuse-deterrent labeling. That designation requires formulation-specific evidence and FDA review.
What is the main manufacturing barrier for a generic product?
Controlled-substance compliance is a major barrier. The manufacturer must manage DEA registration, quota allocation, secure inventory, diversion controls, validated processes, and supply-chain reporting.
Can a formulation patent block all generic hydrocodone-homatropine products?
Usually not. A valid patent may block a specific formulation, use, or process. Generic applicants may avoid infringement through a different excipient system, a label carve-out, or a different manufacturing process, subject to FDA and patent-law requirements.
References
-
U.S. Food and Drug Administration. (2024). Hycodan prescribing information: Hydrocodone bitartrate and homatropine methylbromide oral solution and tablets. FDA.
-
U.S. Food and Drug Administration. (2024). Hydrocodone bitartrate and homatropine methylbromide drug labels. DailyMed.
-
U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
-
U.S. Food and Drug Administration. (2024). Applications covered by Section 505(b)(2). FDA.
